{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:27:04Z","timestamp":1794479224524,"version":"4.9.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.surg.2026.110176","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:12:03Z","timestamp":1776201123000},"page":"110176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Using the Fragility Index analysis for assessment of the robustness of evidence in randomized controlled trials cited in the NCCN guidelines for gastric cancer"],"prefix":"10.1016","volume":"196","author":[{"given":"Noam","family":"Kahana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Boaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Horesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Dourado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Aeschbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Hany Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Garoufalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Lo Menzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Wexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul J.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2026.110176_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.surg.2026.110176_bib2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s10555-020-09925-3","article-title":"Gastric cancer: a comprehensive review of current and future treatment strategies","volume":"39","author":"Sexton","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.surg.2026.110176_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.surg.2026.110176_bib4","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.3390\/ijms22073418","article-title":"Gastric cancer: advances in carcinogenesis research and new therapeutic strategies","volume":"22","author":"Seeneevassen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.surg.2026.110176_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317714626","article-title":"Progress in the treatment of advanced gastric cancer","volume":"39","author":"Song","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.surg.2026.110176_bib7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.athoracsur.2020.03.022","article-title":"National comprehensive cancer network guidelines: who makes them? What are they? Why are they important?","volume":"110","author":"Pluchino","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.surg.2026.110176_bib8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jclinepi.2013.10.019","article-title":"The statistical significance of randomized controlled trial results is frequently fragile: a case for a fragility index","volume":"67","author":"Walsh","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.surg.2026.110176_bib9","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1002\/cam4.4029","article-title":"Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations","volume":"10","author":"Wilson","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.surg.2026.110176_bib10","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/lary.27183","article-title":"The fragility of statistically significant findings from randomized trials in head and neck surgery","volume":"128","author":"Noel","year":"2018","journal-title":"Laryngoscope"},{"key":"10.1016\/j.surg.2026.110176_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005755","article-title":"Fragility index in cardiovascular randomized controlled trials","volume":"12","author":"Khan","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.surg.2026.110176_bib12","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS19-P4-15-01","article-title":"Abstract P4-15-01: fragility index of trials supporting approval of breast cancer drugs","volume":"80","author":"Desnoyers","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.surg.2026.110176_bib14","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.surg.2026.110176_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.surg.2026.110176_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3348\/kjr.2022.0061","article-title":"Restricted mean survival time for survival analysis: a quick guide for clinical researchers","volume":"23","author":"Han","year":"2022","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.surg.2026.110176_bib28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00000658-199908000-00006","article-title":"Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group","volume":"230","author":"Bozzetti","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2026.110176_bib29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/bjs.5353","article-title":"Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer","volume":"93","author":"Yu","year":"2006","journal-title":"Br J Surg"},{"key":"10.1016\/j.surg.2026.110176_bib30","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/sj.bjc.6690243","article-title":"Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative group","volume":"79","author":"Cuschieri","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.surg.2026.110176_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","article-title":"Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial","volume":"11","author":"Songun","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/bjs.9345","article-title":"Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer","volume":"101","author":"Degiuli","year":"2014","journal-title":"Br J Surg"},{"key":"10.1016\/j.surg.2026.110176_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1067\/msy.2002.121891","article-title":"A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma","volume":"131","author":"Csendes","year":"2002","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2026.110176_bib34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.sla.0000151892.35922.f2","article-title":"Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial","volume":"241","author":"Huscher","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2026.110176_bib35","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2026.110176_bib37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0360-3016(98)00280-6","article-title":"Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients","volume":"42","author":"Zhang","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.surg.2026.110176_bib38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","article-title":"Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction","volume":"27","author":"Stahl","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib39","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.surg.2026.110176_bib41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","article-title":"Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Fuchs","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.surg.2026.110176_bib43","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib44","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib45","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.surg.2026.110176_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib47","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib48","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","volume":"32","author":"Guimbaud","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib49","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.3531","article-title":"Efficacy and safety of trifluridine\/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial","volume":"6","author":"Ilson","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib53","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2014.58.3930","article-title":"Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses","volume":"33","author":"Park","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib54","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib55","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2026.110176_bib56","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","article-title":"Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection","volume":"30","author":"Smalley","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib57","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1200\/JCO.2007.12.9593","article-title":"Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781","volume":"26","author":"Tepper","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib59","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2026.110176_bib60","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S1470-2045(24)00580-1","volume":"25","author":"Randon","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2024.0207","article-title":"FOLFIRI plus durvalumab with or without tremelimumab in second-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: the PRODIGE 59-FFCD 1707-DURIGAST randomized clinical trial","volume":"10","author":"Tougeron","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib62","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.surg.2026.110176_bib63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib64","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib65","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","article-title":"Preoperative chemoradiotherapy for resectable gastric cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2026.110176_bib66","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.23.02167","article-title":"Neoadjuvant docetaxel, Oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY","volume":"42","author":"Kang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib67","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0426","article-title":"Effect of S-1 plus Oxaliplatin compared with fluorouracil, leucovorin plus Oxaliplatin as perioperative chemotherapy for locally advanced, resectable gastric cancer: a randomized clinical trial","volume":"5","author":"Yu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.surg.2026.110176_bib68","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.21.02242","article-title":"Laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer: a randomized clinical trial","volume":"40","author":"Kim","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110176_bib22","article-title":"Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022)","volume":"5","author":"Sidali","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.surg.2026.110176_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","article-title":"Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations","volume":"31","author":"Greenland","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.surg.2026.110176_bib19","doi-asserted-by":"crossref","DOI":"10.1098\/rsbl.2019.0174","article-title":"The reign of the p-value is over: what alternative analyses could we employ to fill the power vacuum?","volume":"15","author":"Halsey","year":"2019","journal-title":"Biol Lett"},{"key":"10.1016\/j.surg.2026.110176_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamasurg.2018.4318","article-title":"The fragility index in randomized clinical trials as a means of optimizing patient care","volume":"154","author":"Tignanelli","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.surg.2026.110176_bib23","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1007\/s00464-024-11343-3","article-title":"Evaluation of the robustness of randomized controlled trials for the treatment modalities of esophageal cancer using the fragility index - a systematic review","volume":"38","author":"Kahana","year":"2024","journal-title":"Surg Endosc"},{"key":"10.1016\/j.surg.2026.110176_bib24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.21037\/hbsn-21-118","article-title":"Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect","volume":"11","author":"Horesh","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.surg.2026.110176_bib25","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.02.029","article-title":"The fragility index in randomized controlled trials for patent foramen ovale closure in cryptogenic stroke","volume":"28","author":"Topcuoglu","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.surg.2026.110176_bib26","article-title":"The fragility index of randomized controlled trials for preterm neonates","volume":"10","author":"Li","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.surg.2026.110176_bib58","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.arthro.2024.10.007","article-title":"Editorial commentary: the fragility index minimally improves interpretation of the medical literature: a boat made of bricks in a Sea of uncertainty","volume":"4","author":"Cote","year":"2025","journal-title":"Arthroscopy"},{"key":"10.1016\/j.surg.2026.110176_bib27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1177\/2192568220941684","article-title":"How fragile are the results of a trial? The fragility index","volume":"10","author":"Dettori","year":"2020","journal-title":"Glob Spine J"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003960602600098X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003960602600098X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:34:51Z","timestamp":1794476091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003960602600098X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":64,"alternative-id":["S003960602600098X"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2026.110176","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using the Fragility Index analysis for assessment of the robustness of evidence in randomized controlled trials cited in the NCCN guidelines for gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2026.110176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110176"}}